Eli Lilly and Company (LLY)
Eli Lilly is set to acquire Orna Therapeutics for up to $2.4 billion, expanding its pipeline beyond its successful weight loss drug Zepbound. The company is also selling Zepbound vials at a 50% discount to meet demand amidst supply shortages.
About Eli Lilly and Company
Eli Lilly and Company is a global pharmaceutical corporation focused on developing and manufacturing medicines.
Eli Lilly and Company uses the ticker $LLY for trading. Listed in the Stocks category within the Healthcare sectors.
Insights
- Eli Lilly and Company (LLY) sentiment is up 18.57% from the previous week.
Price: $1,040
Price 24-Hour Time-Series Raw Data
Eli Lilly's stock is experiencing an upward trend, hitting a 52-week and all-time high, supported by strong drug performance in the weight loss sector and AI partnerships, despite ongoing competition and pricing discussions.
24-Hour: 0% 7-Day: -3.85% 30-Day: 0.15%
1-Year High: $1,109.90 on 2025-11-25
1-Year Low: $625.70 on 2025-08-08
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
Eli Lilly and Company (LLY) is currently AltRank #149 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [---] [---]
[--] Month: [---] [---]
[--] Months: [---] [---]
[--] Year: [---] no change
1-Year High: [-----] on 2025-03-08
1-Year Low: [--] on 2025-08-13
Galaxy Score: [--]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] +1
1-Year High: [--] on 2025-03-24
1-Year Low: [--] on 2025-04-03
Engagements: [-------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-------]
Daily Average: [---------]
[--] Week: [---------] -39%
[--] Month: [----------] -2.70%
[--] Months: [-----------] +115%
[--] Year: [-----------] +83%
1-Year High: [----------] on 2025-11-11
1-Year Low: [-------] on 2025-03-16
Engagements by network (24h): TikTok: [------] X: [-------] YouTube: [------] News: [---] Reddit: [---] Instagram: [---]
Mentions: [-----] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Week: [-----] -11%
[--] Month: [------] +38%
[--] Months: [-------] +22%
[--] Year: [-------] +115%
1-Year High: [-----] on 2025-07-08
1-Year Low: [---] on 2025-12-07
Mentions by network (24h): TikTok: [---] X: [-----] YouTube: [--] News: [--] Reddit: [--] Instagram: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Eli Lilly and Company (LLY) in the last [--] hours which is down 8.90% from [-----] in the previous [--] hours
Daily Average: [-----]
[--] Week: [-----] -14%
[--] Month: [-----] +45%
[--] Months: [------] +11%
[--] Year: [------] +290%
1-Year High: [-----] on 2025-07-08
1-Year Low: [---] on 2025-03-16
The most influential creators that mention Eli Lilly and Company in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @EliLillyandCo | [--] | [-------] | [--] | [------] |
| @investseekers | [--] | [-----] | [--] | [------] |
| @JKeynesAlpha | [--] | [------] | [--] | [-----] |
| @Chartfest1 | [--] | [-----] | [--] | [-----] |
| @semodough | [--] | [-----] | [--] | [-----] |
| @Tiagogreis | [--] | [-------] | [--] | [-----] |
| @MeadowCapital | [--] | [-----] | [--] | [-----] |
| @cloud_walker200 | [--] | [---] | [--] | [-----] |
| @TradableAstro | [--] | [-----] | [--] | [-----] |
| @BiopharmIQ | [--] | [------] | [--] | [-----] |
Sentiment: 81%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 81%
Daily Average: 74%
[--] Week: 83% +13%
[--] Month: 76% -2%
[--] Months: 76% +14%
[--] Year: 76% +6%
1-Year High: 96% on 2025-07-08
1-Year Low: 8% on 2025-12-15
Most Supportive Themes:
- Weight Loss Drug Success: (50%) Eli Lilly's Mounjaro and Zepbound are experiencing high demand, with potential for oral formulations.
- AI-Driven Drug Discovery: (30%) Eli Lilly is leveraging AI to accelerate drug discovery through partnerships.
- India Investment: (20%) Eli Lilly is expanding its manufacturing and supply chain operations in India.
Most Critical Themes:
- Market Competition: (60%) Eli Lilly faces intense competition in the weight loss drug market, particularly from Novo Nordisk.
- Mounjaro Price Increase: (40%) Concerns exist regarding the increasing price of Mounjaro, potentially impacting accessibility.
Social Dominance: 0.12%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.12%
Daily Average: 0.296%
[--] Week: 0.185% -0.053%
[--] Month: 0.178% -0.12%
[--] Months: 0.178% -0.247%
[--] Year: 0.178% -0.073%
1-Year High: 1.10% on 2025-12-15
1-Year Low: 0.139% on 2025-12-07
Market Dominance: 1.10%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 1.10%
Daily Average: 1%
1-Year High: 1.50% on 2025-03-12
1-Year Low: 0.72% on 2025-08-08
Market Cap: $932,170,985,603
Market Cap 24-Hour Time-Series Raw Data
Current Value: $932,170,985,603
Daily Average: $772,147,212,206
[--] Week: $982,516,186,504 +3.80%
[--] Month: $981,091,716,800 +5.60%
[--] Months: $981,091,716,800 +55%
[--] Year: $981,091,716,800 +29%
1-Year High: $1,044,409,866,830 on 2026-02-04
1-Year Low: $560,868,171,268 on 2025-08-08
Top Eli Lilly and Company News
Top news links shared on social in the last [--] hours
Showing a maximum of [--] news posts without a LunarCrush subscription.
"Lilly Strikes Deal for Orna Therapeutics for Up to $2.4 Billion - Bloomberg Eli Lilly & Co agreed to buy closely held US biotech Orna Therapeutics Inc. for up $2.4 billion in cash its second deal in as many days as the company expands its pipeline beyond its well-known blockbuster obesity drug Zepbound"
News Link @business 2026-02-09T12:18Z 9.8M followers, 17.4K engagements
"Lilly Sells Zepbound Vials at 50% Discount to Meet Weight Loss Drug Demand Eli Lilly & Co. is now selling vials of its blockbuster weight-loss drug Zepbound to patients for as little as $399 a month as it works to overcome supply shortages of wildly popular shots"
News Link @business 2024-08-27T11:00Z 9.8M followers, 99.3K engagements
Top Eli Lilly and Company Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$LLY Strong digesting the big move. [----] level key to hold. https://schrts.co/IVeenYGY https://schrts.co/IVeenYGY"
X Link @OptionsMike 2026-02-16T15:26Z 112.4K followers, [---] engagements
"BlackRocks funds have $1.8 TRILLION invested in just these [--] stocks: [--]. Nvidia: $363 billion [--]. Apple: $314 billion [--]. Microsoft: $291 billion [--]. Amazon: $170 billion [--]. Alphabet Class A: $138 billion [--]. Broadcom: $131 billion [--]. Alphabet Class C: $113 billion [--]. Meta Platforms: $113 billion [--]. Tesla: $94 billion [--]. Eli Lilly: $72 billion Source: BlackRocks latest 13F filings Q4 [----] https://twitter.com/i/web/status/2023412873280868413 https://twitter.com/i/web/status/2023412873280868413"
X Link @anandchokshi19 2026-02-16T15:03Z 171.1K followers, [----] engagements
"What's Happening in US Markets Now (1/2): 1) Chevron explores natural gas in Greece 2) Eli Lilly reports positive cancer drug trial 3) UBS downgrades Edison on valuation concerns 4) Bio-Techne's Ella Platforms gets EU approval 5) Barclays upgrades Analog Devices to 'Overweight'"
X Link @Trendlyne 2026-02-16T14:00Z 33.3K followers, [---] engagements
"$LLY Eli Lillys Retevmo met the primary endpoint in the Phase [--] LIBRETTO [---] study showing a significant event free survival benefit in early stage RET fusion positive lung cancer. Overall survival trended in favor of the drug though data remain early with limited events so far. https://twitter.com/i/web/status/2023379395235455036 https://twitter.com/i/web/status/2023379395235455036"
X Link @tenet_research 2026-02-16T12:50Z 449.4K followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing